Abstract
Joint diseases are common among patients with psoriasis. Psoriatic arthritis, the most important of these, can be defined as a rheumatoid factor-negative inflammatory arthritis associated with psoriasis and has emerged as a specific disease independent from rheumatoid arthritis. Psoriatic arthritis is divided into several clinical subsets, which is helpful in differentiating it from other types of inflammatory arthritis. The prevalence of arthritis in patients with psoriasis may be far higher than the previously accepted average of 7%. In a recent study of 5795 members of the Nordic Psoriasis Associations, the prevalence was found to be 30%. Arthritis has a significant impact on quality of life in patients with psoriasis. These factors should be recognised as they have implications for therapy, since a number of drugs can delay or stop joint damage when given in time. This also applies to the new biologic agents, although at present these therapies are generally restricted to patients non-responsive to other available drugs. Alone or in combination, the new drugs may achieve higher response rates and have better safety profiles than older therapies. However, long-term experience is still lacking and, unfortunately, the new drugs will be far from affordable by all for some time to come.
Similar content being viewed by others
References
Alibert JL. Précis theorique et practique sur les maladies de la peau. Paris: Caille et Ravier, 1818
Cats A. Psoriasis and arthritis. In: Farber EM, Cox A, editors. Psoriasis. Proceedings of the 1st International Symposium. Stanford: Stanford University Press, 1971
Kremer J, Alarcón G, Lightfoot R, et al. Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994; 37: 316–28
Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973; 3: 55–78
Moll JM, Wright V. Familial occurrence of psoriatic arthritis. Ann Rheum Dis 1973; 32: 181–201
Zachariae E, Zachariae H. Psoriatic Arthritis. In: Roenigk H, Maibach H, editors. Psoriasis. New York: Marcel Decker, 1998
Zachariae H, Petersen HO, Kismeyer-Nielsen F, et al. HLA-antigens in pustular psoriasis. Ann Clin Res 1977; 154: 73–7
Yates VM, Watkinson G, Kelman A. Further evidence for association between psoriasis, Crohn’s disease, and ulcerative colitis. Br J Dermatol 1982; 106: 323–30
Hellgren L. Association between rheumatoid arthritis and psoriasis in total populations. Acta Rheum Scand 1969; 15: 316–26
Jurik AG, Helmig O, Graudal H. Skeletal disease, arthro-osteitis in adult patients with pustulosis palmoplantaris. Scand J Rheumatol Suppl 1988; 70: 3–15
Kahn MF, Kahn MA. The SAPHO syndrome. Baillieres’s Clin Rheumatol 1994; 8: 330–83
Lambert JR, Ansell BM, Stephenson E, et al. Psoriatic arthritis in childhood. Clin Rheum Dis 1976; 2: 339–52
Leonard D, O’Duffy J, Rogers R. Prospective analyses of arthritis in patients hospitalised for psoriasis. Mayo Clin Proc 1978; 53: 511–8
Franssen MJ, van den Hoogen FH, Van de Putte LB. Psoriatic arthropathy. In: van de Kerkhof P, editor. Textbook of psoriasis. Oxford: Blackwell Science, 1999
Bennet R. Psoriatic arthritis. In: McCarthy DJ, Koopman WJ, editors. Arthritis and allied conditions. Philadelphia: Lea & Febiger, 1993
Zanolli MD, Wikle JS. Joint complaints in psoriasis patients. Int J Dermatol 1992; 31: 488–91
Zachariae H, Zachariae R, Blomqvist K, et al. Quality of life and prevalence of arthritis reported by 5795 members of the Nordic Psoriasis Associations: data from the Nordic quality of life study. Acta Derm Venereol 2002; 82: 108–13
Veys EM, Mielants H. Current concepts in psoriatic arthritis. Dermatology 1994; 189 Suppl. 2: 35–41
Lambert JR, Wright V, Rajah SM, et al. Histocompatibility antigens in psoriatic arthritis. Ann Rheum Dis 1976; 35: 526–30
Christophers E, Henseler T. Psoriasis type I and type II as subtypes. of nonpustular psoriasis. In: Roenigk H, Maibach H, editors. Psoriasis. New York: Marcel Decker, 1991
Singri P, West DP, Gordon KB. Biologic therapy for psoriasis. Arch Dermatol 2002; 138: 657–63
Espinoza L, Espinoza C, Cuellar M, et al. Fibroblast function in psoriatic arthritis. J Rheumatol 1994; 21: 1502–11
Taccari E, Fatorossi A, Moretti S, et al. Phenotypic profile of major synovial cell populations of long-standing psoriatic arthritis. J Rheumatol 1987; 14: 525–30
Zachariae H. Methotrexate. In: van de Kerkhof P, editor. Textbook of Psoriasis. Oxford: Blackwell Science, 1999
Genestier L. Immunosuppressive properties of methotrexate apoptosis and clonal deletion of activated peripheral T-cells. J Clin Invest 1998; 102: 322–8
Cuellar ML, Espinoza LR. Methotrexate use in psoriasis and psoriatic arthritis. Rheum Dis Clin North Am 1997; 23: 797–809
Roenigk HH, Auerbach R, Maibach H, et al. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998; 38: 478–85
Whiting-O’Keefe Q, Fye K, Sach K. Methotrexate and histologic hepatic abnormalities: a metaanalysis. Am J Med 1991; 90: 711–6
Lebwohl M, Ellis G, Gottlieb A, et al. Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. J Am Acad Dermatol 1998; 39: 464–75
Zachariae H. Renal toxicity of long-term cyclosporin. Scand J Rheumatol 1999; 28: 65–8
Cheregato GC, Leoni A. Treatment of psoriatic arthropathy with etretinate, a two year follow-up. Acta Derm Venereol 1986; 66: 321–4
Perlman SG, Gerber LH, Roberts RM, et al. Photo chemotherapy and psoriatic arthritis. Ann Intern Med 1979; 91: 717–22
Farr M, Kitas G, Waterhouse L, et al. Sulfalazine in psoriatic arthritis: a double-blind placebo-controlled study. Br J Rheumatol 1990; 29: 46–9
Clegg DO, Reda DJ, Mejlas E, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. Arthritis Rheum 1996; 39: 2013–20
Feldges DH, Barnes CJ. Treatment of psoriatic arthropathy with either azathioprine or methotrexate. Rheumatol Rehab 1974; 13: 120–4
Luzar MJ. Hydroxychloroquine in psoriatic arthropathy: exacerbations of psoriatic skin lesions. J Rheumatol 1982; 9 (3): 462–4
Seideman P, Fjellner B, Johannesson A. Psoriatic arthritis treated with oral colchicine. J Rheumatol 1987; 14 (4): 777–9
Lebwohl M. New developments in the treatment of psoriasis. Arch Dermatol 2002; 138: 686–8
Prashant S, West DP, Gordon KB. Biologic therapy for psoriasis, the new therapeutic frontier. Arch Dermatol 2002; 138: 657–63
Krueger G. Selective targeting of T cell subsets: focus on alefacept: a remittive therapy for psoriasis. Expert Opin Biol Ther 2002; 2: 431–44
Ellis CN, Krueger G. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. NEJM 2001; 345: 248–55
Dinant HJ, van Kuijk AW, Goedkoop AY, et al. Alefacept (LFA3-IgG1 fusion protein, LFA3TIP) reduces synovial inflammatory infiltrate and improves outcome in psoriatic arthritis [abstract 233]. Arthritis Rheum 2001; 9 Suppl.: s91
Stein C, Pincus T, Yocum D, et al. Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks: an open-label extension study. The methotrexate-cyclosporine combination study group. Arthritis Rheum 1997, 3
Clark C, Kirby B, Morris A, et al. Combination treatment with methotrexate and cyclosporine for severe recalcitrant psoriasis. Br J Dermatol 1999; 141: 279–82
Finlay AY, Coles EC. The effects of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995; 132: 236–44
Acknowledgements
The study ‘Quality of life and prevalence of arthritis reported by 5795 members of the Nordic Psoriasis Association’, quoted in reference 17, inspired this article. The contribution by my co-workers to the ‘Nordic quality of life study’: Robert Zachariae, Kirsti Blomqvist, Steingrimur Davidsson, Lars Molin, Cato Mørk and Bardur Sigurgeirsson is gratefully acknowledged. So is the initiative and support given by the Nordic Psoriasis Associations to the ‘Quality of Life’ study together with a grant by Leo Pharmaceutical Products Ltd, Ballerup, Denmark. The author of this paper has previously participated in clinical trials on cyclosporine, sponsored by Sandoz Pharma Ltd, Basle, and is at present participating in a clinical trial on efalizumab carried out by Serono International S.A., Geneva. No sources of funding, however, have been used to assist in the preparation of this manuscript, and no potential conflicts of interest that the author may have are directly relevant to the contents of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zachariae, H. Prevalence of Joint Disease in Patients with Psoriasis. Am J Clin Dermatol 4, 441–447 (2003). https://doi.org/10.2165/00128071-200304070-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128071-200304070-00001